Market expectations of a decline in Henan Taloph Pharmaceutical's revenue performance and slower growth compared to the industry average may contribute to its low P/S ratio. Shareholders' wariness of the company's ability to keep up with industry growth could be a factor in the declining share price.

Henan Taloph's lower P/S ratio may be justified due to slower growth rates than industry rivals. Doubts about the company's ability to maintain robust growth in line with industry may hinder share price recovery.